Doxofylline

Summary

Doxofylline (CHEMBL1527608) is a phase-3 clinical-stage small-molecule bronchodilator agent (ATC R03DA11); indicated across 2 conditions including obstructive lung disease and asthma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: R03DA11
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 266.25 Da · C11H14N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1527608
Name	Doxofylline
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	50942
ChEBI	CHEBI:94714
ATC	R03DA11
Molecular formula	C11H14N4O4
Molecular weight	266.25
InChIKey	HWXIGFIVGWUZAO-UHFFFAOYSA-N

SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3

IUPAC name: 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione

ChEBI definition: An oxopurine that is a derivative of xanthine, methylated at N-1 and N-3 and carrying a 1,3-dioxolan-2-ylmethyl group at N-7, used in the treatment of asthma.

Pharmacological roles (ChEBI): bronchodilator agent, antitussive, anti-asthmatic drug.

Also known as: ABC 12/3, ABC-12/3, Ansimar, Dioxyfilline, Doxofilina, Doxofylline, Doxophylline, NSC-759645, Synasma, Ventax, SID49645880, SID29215238

Parent form; salt/anhydrous children: CHEMBL5174400, CHEMBL5183499

Patent coverage: 898 distinct patent families (2,681 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Histone-lysine N-methyltransferase 2A.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obstructive lung disease	3	MONDO:0002267	HP:0006536
asthma	3	MONDO:0004979	MONDO:0004979

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04238221	PHASE4	NOT_YET_RECRUITING	Effect of add-on Doxofylline on Lung Function in Stable COPD
NCT03388853	PHASE4	COMPLETED	Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD.
NCT06346691	PHASE4	COMPLETED	Effects of Oral Doxofylline and Procaterol on Chronic Obstructive Pulmonary Disease
NCT03879590	PHASE3	UNKNOWN	Efficacy Of Doxophylline As A Sparing Treatment For Inhaled Corticosteroids In Mexican Children With Asthma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).